Happy World Menopause Awareness Day!
At Medherant, we're committed to empowering women through knowledge and innovative solutions for managing menopause. Did you know that peri-menopause and menopause affects over 13 million women in the UK? At Medherant, we're committed to raising a...
Start of dosing in clinical study of Medherant’s testosterone patch for post-menopausal women
13 October 2023 (Coventry, UK). Medherant is pleased to announce that the Phase I study of its testosterone patch for post-menopausal women has been initiated at Hammersmith Medicines Research (HMR; London). The first group of volunteers has been ...
Approval of Clinical Trial Application for Phase I study of Medherant’s testosterone patch for post-menopausal women
2 October 2023 (Coventry, UK). Medherant is pleased to announce that approval has been received from MHRA and the Research Ethics Committee for the Clinical Trial Application for a Phase I study in healthy post-menopausal women of Medherant’s testo...
Medherant New Appointments (September 2023)
Medherant appoints Karolina Afors as Medical Director and Fran Crawford joins as a non-executive director 11 September 2023 (Coventry, UK). Medherant announces that Dr Karolina Afors BSC MBBS MRCOG has joined the company in the newly-created ...
Medherant secures further funding for development of testosterone patch for post-menopausal women
3 April 2023. Medherant (Coventry, UK) announces that it has raised £2.9m of new funding from investors in a financing round led by Mercia Asset Management. Medherant will principally use the funding to progress development of a testosterone tr...